The development of NO donors with site-specific and time-controlled propert
ies is of great interest. We have designed a novel prodrug class as possibl
e agents against metastatic prostate cancer by coupling a diazeniumdiolate
to the terminal carboxyl groups of amino acids or peptides, such as Ser-Ser
-Tyr-Tyr, Ser-Ser-Phe-Tyr, and Gly-Ile-Ser-Ser-Phe-Tyr. These prodrugs can
be activated by alpha -chymotrypsin or prostate specific antigen and are po
tentially potent compounds for prostatic cancer. (C) 2001 Published by Else
vier Science Ltd.